245 related articles for article (PubMed ID: 28077045)
1. Association of time to antibiotics and clinical outcomes in adult hematologic malignancy patients with febrile neutropenia.
Butts AR; Bachmeier CC; Dressler EV; Liu M; Cowden A; Talbert J; Adams VR
J Oncol Pharm Pract; 2017 Jun; 23(4):278-283. PubMed ID: 28077045
[TBL] [Abstract][Full Text] [Related]
2. Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia.
Daniels LM; Durani U; Barreto JN; O'Horo JC; Siddiqui MA; Park JG; Tosh PK
Support Care Cancer; 2019 Nov; 27(11):4171-4177. PubMed ID: 30805726
[TBL] [Abstract][Full Text] [Related]
3. Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit.
Cumpston A; Craig M; Hamadani M; Abraham J; Hobbs GR; Sarwari AR
Transpl Infect Dis; 2013 Apr; 15(2):142-9. PubMed ID: 23279656
[TBL] [Abstract][Full Text] [Related]
4. Outcomes Associated with De-escalation of Antibiotics to Target Positive Cultures when Treating Febrile Neutropenia.
Rainess R; Campbell P; Santamala J; Kubin CJ; Mehta M
J Pharm Pract; 2024 Apr; 37(2):301-306. PubMed ID: 36201023
[No Abstract] [Full Text] [Related]
5. A retrospective analysis of clinical acuity markers on hospital length of stay in patients with febrile neutropenia.
Johannesmeyer HJ; Seifert CF
J Oncol Pharm Pract; 2019 Apr; 25(3):535-543. PubMed ID: 29207937
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of imipenem 1.5 g daily in febrile patients with short duration neutropenia after chemotherapy for non-leukemic hematologic malignancies and solid tumors: personal experience and review of the literature.
Jourdan E; Defez C; Topart D; Richard B; Bellabas H; Fabbro-Peray P; Jourdan J; Sotto A
Leuk Lymphoma; 2003 Apr; 44(4):619-26. PubMed ID: 12769338
[TBL] [Abstract][Full Text] [Related]
7. Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode.
Demirel A; Tabak F; Ar MC; Mete B; Öngören Ş; Yemişen M; Özaras R; Eşkazan E; Başlar Z; Mert A; Soysal T; Ferhanoğlu B; Aydın Y; Öztürk R
Turk J Haematol; 2015 Sep; 32(3):243-50. PubMed ID: 25913035
[TBL] [Abstract][Full Text] [Related]
8. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.
Wrenn RH; Cluck D; Kennedy L; Ohl C; Williamson JC
J Oncol Pharm Pract; 2018 Apr; 24(3):170-175. PubMed ID: 28077047
[TBL] [Abstract][Full Text] [Related]
9. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
[TBL] [Abstract][Full Text] [Related]
10. The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies.
Kaya S; Köksal I; Menteşe A; Sönmez M; Sümer A; Yıldırım SS; Yılmaz G
Int J Infect Dis; 2013 Nov; 17(11):e1056-9. PubMed ID: 23742830
[TBL] [Abstract][Full Text] [Related]
11. The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies.
Calik S; Ari A; Bilgir O; Cetintepe T; Yis R; Sonmez U; Tosun S
Saudi Med J; 2018 Sep; 39(9):878-885. PubMed ID: 30251730
[TBL] [Abstract][Full Text] [Related]
12. Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies.
Stohs EJ; Abbas A; Freifeld A
Transpl Infect Dis; 2024 Apr; 26(2):e14236. PubMed ID: 38349035
[TBL] [Abstract][Full Text] [Related]
13. Extended vs Bolus Infusion of Broad-Spectrum β-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial.
Ram R; Halavy Y; Amit O; Paran Y; Katchman E; Yachini B; Kor S; Avivi I; Ben-Ami R
Clin Infect Dis; 2018 Sep; 67(8):1153-1160. PubMed ID: 29608680
[TBL] [Abstract][Full Text] [Related]
14. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.
Le Clech L; Talarmin JP; Couturier MA; Ianotto JC; Nicol C; Le Calloch R; Dos Santos S; Hutin P; Tandé D; Cogulet V; Berthou C; Guillerm G
Infect Dis (Lond); 2018 Jul; 50(7):539-549. PubMed ID: 29451055
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of empiric antibiotic de-escalation in febrile neutropenia.
Kroll AL; Corrigan PA; Patel S; Hawks KG
J Oncol Pharm Pract; 2016 Oct; 22(5):696-701. PubMed ID: 26227319
[TBL] [Abstract][Full Text] [Related]
16. Urine cultures at the onset of febrile neutropenia rarely impact antibiotic management in asymptomatic adult cancer patients.
Grigg SE; Date P; Loh Z; Estacio O; Johnson DF; Hawkes EA; Grigg A
Support Care Cancer; 2019 Apr; 27(4):1223-1227. PubMed ID: 30259115
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated with Survival Outcomes of Febrile Neutropenia in Hematologic Malignancy Patients.
Weerasubpong B; Makruasi N; Linasmita P; Rattanamongkolgul S
J Med Assoc Thai; 2016 Nov; 99 Suppl 8():S53-S62. PubMed ID: 29901912
[TBL] [Abstract][Full Text] [Related]
18. Febrile Neutropenia: Decreasing Time to Antibiotic Administration in a Community Hospital Emergency Department.
Bruce SD
Clin J Oncol Nurs; 2021 Feb; 25(1):23-26. PubMed ID: 33480869
[TBL] [Abstract][Full Text] [Related]
19. Time to antibiotics and outcomes in cancer patients with febrile neutropenia.
Perron T; Emara M; Ahmed S
BMC Health Serv Res; 2014 Apr; 14():162. PubMed ID: 24716604
[TBL] [Abstract][Full Text] [Related]
20. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
Baskaran ND; Gan GG; Adeeba K
Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
